INTRODUCTION
============

Infection has attracted attention as a novel risk factor for atherosclerosis, which is different from traditional risk factors.[@B1] Among various infectious agents, *Chlamydia pneumoniae* (*C. pneumoniae*) is the major infectious agent that has been extensively investigated. Seroepidemiological studies showed that the seropositivity of anti-*C. pneumoniae* antibodies is two times higher in patients with cardiovascular diseases than that of healthy population controls.[@B2] Furthermore *C. pneumoniae* were isolated from more than half of atherosclerotic lesions.[@B3] *In vitro* studies suggest that *C. pneumoniae* could be detected in circulating leukocytes, and that they infect all atheroma cell types such as endothelial cells, vascular smooth muscle cells (VSMC), and macrophages,[@B4]-[@B6] and induce the inflammatory cytokines, procoagulants, matrix metalloproteinases and adhesion molecules.[@B7]-[@B9]

Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily that regulates lipid and lipoprotein metabolism and glucose homeostasis. In addition, PPARγ has been reported to be an important modulator of the inflammatory response of vessel wall not only through metabolic effects but also through their direct action in vascular and inflammatory cells.[@B10],[@B11] PPARγ is expressed in the major cellular constituents of the vessel wall such as endothelial cells, VSMC, and macrophages, and affects development of atherosclerosis.[@B12],[@B13] In endothelial cells, PPARγ agonist inhibits the expression of monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1.[@B14],[@B15] PPARγ also interferes with leukocyte chemoattraction and recruitment to atherosclerotic lesions and suppresses the expression of inducible nitric oxide synthase and matrix metalloproteinase-9 (MMP-9) in macrophages. Furthermore, PPARγ inhibits VSMC proliferation by attenuating the mitogen-induced degradation of p27Kip1, and platelet-derived growth factor-induced VSMC migration by inhibiting MMP-9 expression.[@B11],[@B16]

Although a number of studies indicate the role of PPARγ in the modulation of vascular inflammation, the effect of atheroprone infectious agents on the expression of PPARγ in vascular cells has not yet been studied. Interestingly, infection increases PPARγ expression in porcine white blood cells[@B17] but down-regulates it in murine adipocytes,[@B18] suggesting that PPARγ expression is differentially regulated according to cell types. We hypothesized that *C. pneumoniae* infection, which is a clear risk factor for the development of atherosclerosis, may have an effect on the expression of PPARγ in vascular smooth muscle cells. Therefore, the present study was undertaken to investigate whether *C. pneumoniae* infection could affect the expression of PPARγ in human coronary artery smooth muscle cells (HCSMC).

MATERIALS AND METHODS
=====================

Cell lines
----------

Human coronary artery smooth muscle cells (HCSMC) were purchased from Clonetics and cultured in SmBm media (smooth muscle cell basal media, Clonetics, Walkersville, MD, USA). Passages between 5 and 10 were used.

C. pneumoniae
-------------

*C. pneumoniae* AR-39 strain was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The organisms were inoculated into shell vials containing McCoy cells (ATCC, Manassas, VA, USA), and then shell vials were centrifuged at 1500g for 1 hour and incubated in RPMI 1640 medium containing 1 µg/mL cycloheximide (Sigma, St. Louis, MO, USA). After 48 hours, the infected cells were disrupted by ultrasonication, and culture supernatants and cell debris were removed by centrifugation at 800g for 10 minutes. The organisms were then concentrated by a high-speed centrifugation at 30,000g for 30 minutes. The bacterial pellets were resuspended in sucrose phosphate glutamate transport medium and stored at -70℃ until use. The organisms resuspended in RPMI 1640 medium were used for experiments. The number of infectious *C. pneumoniae* was determined as inclusion forming units per mL by counting chlamydial inclusions formed in McCoy cells with fluorescein isothiocyanate-conjugated *C. pneumoniae*-specific monoclonal antibody (DAKO, Copenhagen, Denmark).

Infection of HCSMC with *C. pneumoniae*
---------------------------------------

HCSMCs were trypsinized and plated at a density of 4 × 10^5^ cells/well on 6-well plates. Once confluent, the medium was then changed to serum-free medium for 24 hour to achieve synchronous growth arrest. HCSMCs were inoculated with *C. pneumoniae* at a multiplicity of infection (MOI) of 2, and the plates were centrifuged at 500g for 1 hour at room temperature. Multiple inclusion bodies in HCSMCs were observed after 48 hours of *C. pneumoniae* infection.

Cell proliferation assay
------------------------

HCSMCs were plated at a density of 5 × 10^3^ cells/well on 96-well plates and inoculated with *C. pneumoniae* by the method described above. Cell proliferation was determined using XTT proliferation assay kit (JBI, Deagu, Korea) 6 hours, 24 hours and 48 hours after inoculation. As a control for cell proliferation, noninfected HCSMCs were used. To determine the effect of a PPARγ agonist on the proliferation of *C. pneumoniae*-infected HCSMCs, rosiglitazone (GlaxoSmithKline Corporate, King of Prussia, PA, USA) at various concentrations was applied 1 hour before inoculation.

Real time reverse transcription-polymerase chain reaction (RT-PCR)
------------------------------------------------------------------

Total RNA was extracted from HCSMCs using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. Total extracted RNA was subjected to reverse transcription using an onestep RT kit (Invitrogen). Expressions of PPARγ and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were examined in real time PCR using an SYBR Green dye. Primers used were as follows: human PPARγ sense, 5\'-TCTCTC CGTAATGGAAGACC-3\', human PPARγ antisense, 5\'-CCCCTACAGAGTATTACG-3\'; GAPDH sense, 5\'-TGCACCACCAACTGCTTAGC-3\', GAPDH antisense 5\'-GGCATGGACTGTGGTCAT GAG-3\'. To examine the changes in the expression of PPARγ mRNA according to time elapse after *C. pneumoniae* infection in HCSMCs, relative values were compared at various time intervals.

Western blot analysis
---------------------

HCSMCs were seeded at 4 × 10^5^ cells/well in 6-well plates and incubated with *C. pneumoniae*. After various time intervals, cells were harvested,lysed, and sonicated in Tris-lysate buffer \[20 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 mM Na~2~P~2~O~7~, 100 mM NaF, 2 mM Na~3~VO~4~, 1 mM phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin\]. Cell lysate were cleared by centrifugation, and protein concentrations were determined by Bradford protein assay kit (Pierce, Rockford, IL, USA). Proteins were resolved on a 9% sodium dodecylsulfate-polyacrylamide gel, and electrophorectically transferred onto a nitrocellulose membrane. The membrane was incubated with anti-PPARγ monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). HRP-conjugated anti-mouse IgG (Amersham Bioscience, Piscataway, NJ, USA) was used as a secondary antibody. The antigen-antibody complexes were detected using enhanced chemilumnescence kit (Amersham Bioscience). Quantification of the protein band was done by densitometry.

Statistics
----------

Statistical analysis was performed using the Statistical Package for Social Sciences (version 10, SPSS Inc., Chicago, IL, USA). Values of continuous variables are expressed as mean ± standard deviation. Comparisons of data were made using Student t-test. *P*-values less than 0.05 were considered as indicative of statistical significance.

RESULTS
=======

*C. pneumoniae* stimulates HCSMCs proliferation
-----------------------------------------------

HCSMC proliferation was compared between *C. pneumoniae*-infected and uninfected-HCSMCs, according to time intervals such as 6, 24, and 48 hours after infection at a MOI of 2. As shown in [Fig. 1](#F1){ref-type="fig"}, HCSMCs proliferation was stimulated after inoculation with *C. pneumoniae* in a time-dependent manner. At 48 hours, XTT assay showed that *C. pneumoniae* significantly increased the number of HCSMCs compared to the uninfected control ([Fig. 1](#F1){ref-type="fig"}).

Rosiglitazone suppresses *C. pneumoniae*-induced proliferation of HCSMCs.
-------------------------------------------------------------------------

To explore whether PPARγ activation directly affects *C. pneumoniae*-induced HCSMCs proliferation, the proliferation rate was compared between *C. pneumoniae*-infected HCSMCs and rosiglitazone-treated *C. pneumoniae*-infected HCSMCs. Treatment of HCSMCs with 10 and 50 µM rosiglitazone significantly decreased the *C. pneumoniae*-induced proliferation of HCSMCs from 5 hours after *C. pneumoniae* infection and from 8 hours even at 1 µM concentration ([Fig. 2](#F2){ref-type="fig"}).

*C. pneumoniae* upregulates the expression of PPARγ mRNA expression in HCSMCs
-----------------------------------------------------------------------------

To determine whether *C. pneumoniae* activates PPARγ mRNA in HCSMCs, cells were left untreated or stimulated with *C. pneumoniae*, and cDNA was then prepared from each HCSMCs after 3-, 6-, and 24-hour exposure to *C. pneumoniae*. The expression of PPARγ mRNA was evaluated by real time RT-PCR. The levels of PPARγ mRNA were significantly increased in HCSMCs 3 hours after *C. pneumoniae* inoculation, and remained elevated until 6 hours after infection as compared with uninfected control. At 24 hours, the level of PPARγ mRNA in HCSMCs infected with *C. pneumoniae* returned to the level of uninfected control ([Fig. 3](#F3){ref-type="fig"}).

*C. pneumoniae* stimulates the expression of PPARγ protein in HCSMCs
--------------------------------------------------------------------

To investigate whether *C. pneumoniae* infection affects PPARγ protein expression in HCSMCs, cells were stimulated with *C. pneumoniae* infection for 3, 6, and 24 hours. Cell lysates were analyzed by Western blot using a anti-PPARγ monoclonal antibody. The levels of PPARγ protein were already increased in HCSMCs after 3-hour exposure to *C. pneumoniae* as compared with uninfected HCSMCs, and the status of elevation was maintained until 24 hours ([Fig. 4](#F4){ref-type="fig"}).

PPARγ activator further increases the expression of PPARγ protein in *C. pneumoniae*-infected HCSMCs
----------------------------------------------------------------------------------------------------

The observation that *C. pneumoniae* has a stimulatory effect on PPARγ protein in HCSMCs prompted us to investigate the potential synergistic effect of rosiglitazone on the expression of PPARγ in HCSMCs. Thus, HCSMC cells were divided into untreated control, *C. pneumoniae*-inoculated, rosiglitazone (20 µM)-treated, and co-treated with both rosiglitazone and *C. pneumoniae*. Changes in the expression of PPARγ in each HCSMCs were evaluated by Western blot 24 hours after treatment. As compared with untreated control, both rosiglitazone and *C. pneumoniae* significantly increased the expression of PPARγ protein in HCSMCs. Interestingly, co-treatment of HCSMCs with rosiglitazone and *C. pneumoniae* resulted in an additive effect on the expression of PPARγ protein ([Fig. 5](#F5){ref-type="fig"}).

DISCUSSION
==========

The present study shows that *C. pneumoniae* could upregulate the expression of PPARγ mRNA and protein in HCSMCs, and PPARγ activator further increased its expression in concert with *C. pneumoniae*. In addition, rosiglitazone significantly attenuated *C. pneumoniae*-induced proliferation of HCSMCs. Our results suggest that PPARγ palys a role in the development of atherosclerosis induced by *C. pneumoniae*. It is suggested that rosiglitazone, a PPARγ agonist, could prevent the development of atherosclerosis through its anti-inflammatory and anti-atherogenic effects.

*C. pneumoniae* could infect and proliferate within endothelial cells, vascular smooth muscle cells, and macrophages, and evoke inflammatory response in these cells.[@B4]-[@B9] Animal model studies have shown that *C. pneumoniae* could infect vessel wall and cause arterial inflammation, which leads to the initiation and development of atherosclerotic lesions.[@B19],[@B20] In contrast, PPARγ has an important effect of inhibiting growth and migration of all vascular cells, and reducing vessel inflammation, which leads to attenuation of atherosclerosis in the vessel wall.[@B12],[@B13],[@B16],[@B21]-[@B23] However, the influence of *C. pneumoniae* infection on the PPARγ in atherosclerosis-related vascular cells has not yet been studied. Since PPARγ is expressed in all vascular cells and has significant effects on the protection from vessel inflammation, it is of value to demonstrate the effect of *C. pneumoniae* on the PPARγ in vascular cells.

Few studies have evaluated the association between infection and PPARγ. Leininger et al. reported that *in vivo* lipopolysaccharide challenge caused a dynamic increase in PPARγ protein expression in peripheral white blood cells.[@B17] In tissues of Helicobacter pylori-induced atrophic gastritis or gastric carcinoma, the expression of PPARγ was upregulated,[@B24] and Huang B et al. showed that the expression of PPARγ was upregulated in the endothelial cells in mice infected with *C. pneumoniae*.[@B25] In the present study, we also observed that *C. pneumoniae* stimulated the expression of PPARγ in vascular smooth muscle cells. This observation was contrary to the expectation that *C. pneumoniae* might suppress the expression of PPARγ because of their counter-balancing actions on all the vascular cells and vessel walls. However, the mechanisms of *C. pneumoniae*-induced PPARγ activation in HCSMCs are not clear. *C. pneumoniae* is a Gram-negative bacterium, and its cell wall is rich in lipopolysaccharides, which can induce hepatocytes and macrophages to secret prostaglandin (PG) D~2~.[@B26],[@B27] 15d-PGJ~2~, a metabolite of PGD~2~, is a ligand for PPARγ and can induce the PPARγ expression. Further study is needed to elucidate in detail the mechanism of *C. pneumoniae*-induced PPARγ upregulation *in vitro*.

The increase of PPARγ expression may act as an counter-regulatory mechanism of attenuating the negative effect of *C. pneumoniae* in HCSMCs. Rosiglitazone suppressed *C. pneumoniae*-induced proliferation of HCSMCs and further elevated the expression of PPARγ protein. It might be a novel mechanism of PPARγ activators to be protective against the atheroprone *C. pneumoniae*. Further studies are required to clarify the association and influence between infection and PPARγ in vascular cells as well as in animal models.
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![Cell proliferation assay of HCSMCs infected with Chlamydia pneumoniae. Cell proliferation was assessed by XTT proliferation assay kit (JBI, Daegu, Korea). Changes in cell proliferation are expressed by a percentage of the mean value of control (uninfected HCSMCs). ^\*^*p* \< 0.05.](ymj-49-230-g001){#F1}

![Dose-dependent effects of rosiglitazone on the proliferation of HCSMCs infected with *Chlamydia pneumoniae* during 24 hours. ^\*^*p* \< 0.05.](ymj-49-230-g002){#F2}

![Real time RT-PCR of PPARγ in HCSMCs infected with *Chlamydia pneumoniae*. Relative value was arbitarily defined as corrected for GAPDH mRNA value. CP represents *Chlamydia pneumoniae*. ^\*^*p* \< 0.05 vs CP(-).](ymj-49-230-g003){#F3}

![Western blot analysis of PPARγ in HCSMCs infected with *Chlamycia pneumoniae*. After 3, 6, and 24 hours, cells were subjected to 10% SDS-PAGE and blotted with anti-PPARγ monoclonal antibody. Expression levelsof PPARγ were quantified by densitometry. ^\*^*p* \< 0.05 vs CP(-).](ymj-49-230-g004){#F4}

![Western blot analysis of PPARγ in HCSMCs infected with *Chlamydia pneumoniae* and/or treated with rosiglitazone (20 µM). After 24 hours, cells were subjected to 10% SDS-PAGE and blotted with anti-PPARγ monoclonal antibody. Expression levels of PPARγ were quantified by densitometry. ^\*^*p* \< 0.05 vs CP(-).](ymj-49-230-g005){#F5}
